- Home
- ZURA vs ITRG Comparison
ZURA vs ITRG Comparison
Compare ZURA & ITRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | ITRG |
|---|---|---|
| Founded | 2022 | 1997 |
| Country | United States | Canada |
| Employees | 40 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 529.9M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ZURA | ITRG |
|---|---|---|
| Price | $5.12 | $2.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $13.00 | $5.13 |
| AVG Volume (30 Days) | 1.7M | ★ 4.0M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $67.34 |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | ★ N/A | $45.07 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $1.43 |
| 52 Week High | $7.25 | $4.87 |
Technical Indicators
Market Signals| Indicator | ZURA | ITRG |
|---|---|---|
| Relative Strength Index (RSI) | 59.46 | 46.90 |
| Support Level | $4.22 | $2.32 |
| Resistance Level | $5.82 | $2.97 |
| Average True Range (ATR) | 0.46 | 0.16 |
| MACD | 0.20 | -0.02 |
| Stochastic Oscillator | 66.40 | 32.89 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.